AU2019406702B2 - An optimized acceptor splice site module for biological and biotechnological applications - Google Patents

An optimized acceptor splice site module for biological and biotechnological applications

Info

Publication number
AU2019406702B2
AU2019406702B2 AU2019406702A AU2019406702A AU2019406702B2 AU 2019406702 B2 AU2019406702 B2 AU 2019406702B2 AU 2019406702 A AU2019406702 A AU 2019406702A AU 2019406702 A AU2019406702 A AU 2019406702A AU 2019406702 B2 AU2019406702 B2 AU 2019406702B2
Authority
AU
Australia
Prior art keywords
sequence
nucleotides
nucleic acid
acceptor splice
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019406702A
Other languages
English (en)
Other versions
AU2019406702A1 (en
Inventor
Elvir BECIROVIC
Martin Biel
Stylianos MICHALAKIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veongen Therapeutics GmbH
Original Assignee
Veongen Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veongen Therapeutics GmbH filed Critical Veongen Therapeutics GmbH
Publication of AU2019406702A1 publication Critical patent/AU2019406702A1/en
Application granted granted Critical
Publication of AU2019406702B2 publication Critical patent/AU2019406702B2/en
Assigned to VeonGen Therapeutics GmbH reassignment VeonGen Therapeutics GmbH Request to Amend Deed and Register Assignors: VIGENERON GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019406702A 2018-12-20 2019-12-19 An optimized acceptor splice site module for biological and biotechnological applications Active AU2019406702B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18214415.4 2018-12-20
EP18214415 2018-12-20
PCT/EP2019/086454 WO2020127831A1 (en) 2018-12-20 2019-12-19 An optimized acceptor splice site module for biological and biotechnological applications

Publications (2)

Publication Number Publication Date
AU2019406702A1 AU2019406702A1 (en) 2021-06-10
AU2019406702B2 true AU2019406702B2 (en) 2025-12-18

Family

ID=64755152

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019406702A Active AU2019406702B2 (en) 2018-12-20 2019-12-19 An optimized acceptor splice site module for biological and biotechnological applications

Country Status (10)

Country Link
US (1) US12502438B2 (cg-RX-API-DMAC10.html)
EP (1) EP3898996A1 (cg-RX-API-DMAC10.html)
JP (2) JP7668737B2 (cg-RX-API-DMAC10.html)
KR (1) KR102938671B1 (cg-RX-API-DMAC10.html)
CN (1) CN113474460A (cg-RX-API-DMAC10.html)
AU (1) AU2019406702B2 (cg-RX-API-DMAC10.html)
CA (1) CA3122909A1 (cg-RX-API-DMAC10.html)
IL (1) IL284021B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202106356QA (cg-RX-API-DMAC10.html)
WO (1) WO2020127831A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898996A1 (en) * 2018-12-20 2021-10-27 Vigeneron GmbH An optimized acceptor splice site module for biological and biotechnological applications
CA3135490A1 (en) 2019-03-29 2020-10-08 Salk Institute For Biological Studies High-efficiency reconstitution of rna molecules
JP7866981B2 (ja) * 2020-07-14 2026-05-28 アビオナ・セラピュ―ティクス・インコーポレイテッド 多部分遺伝子送達のための組み換えアデノ随伴ウイルスベクター
US20230374476A1 (en) * 2021-02-05 2023-11-23 University Of Massachusetts Prime editor system for in vivo genome editing
EP4323391A4 (en) * 2021-04-15 2025-04-16 Tacit Therapeutics, Inc. HIGH-EFFICIENCY TRANS-SPLICING FOR TARGETED RNA SEQUENCE REPLACEMENT IN HUMAN CELLS
US20240216544A1 (en) * 2021-05-14 2024-07-04 Salk Institute For Biological Studies Methods and compositions for expression of editing proteins
CN120569476A (zh) 2022-11-30 2025-08-29 安铂生物公司 用于靶向反式剪接的方法和组合物
CN116463380A (zh) * 2023-03-30 2023-07-21 中国科学院深圳先进技术研究院 一种重组腺相关病毒载体组合物、外源基因表达系统及方法
US12655424B2 (en) 2024-02-05 2026-06-16 Amber Bio Inc. Methods and compositions for trans-splicing utilizing small nuclear RNAs and small nucleolar RNAs
CN121674392A (zh) * 2025-10-23 2026-03-17 中国科学院深圳先进技术研究院 反式剪接系统及其用途
US12686869B1 (en) 2026-01-23 2026-07-21 Amber Bio Inc. Methods and compositions for trans-splicing utilizing trifunctional elements

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
WO2014170480A1 (en) * 2013-04-18 2014-10-23 Fondazione Telethon Effective delivery of large genes by dual aav vectors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US20030077754A1 (en) * 1995-12-15 2003-04-24 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
JP2009000120A (ja) * 1998-08-13 2009-01-08 Virxsys Corp スプライソソーム媒介rnaトランス−スプライシングにおける使用のための方法及び組成物
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
GB9906615D0 (en) 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
CA2477295A1 (en) 2002-02-25 2003-09-04 Intronn, Inc. Trans-splicing mediated imaging of gene expression
US7968334B2 (en) 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
EP2486136B1 (en) 2009-10-08 2016-03-30 Association Institut de Myologie Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
JP2014525754A (ja) 2011-08-12 2014-10-02 バイレクシス コーポレイション アポトーシスを誘導するための組成物および方法
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
EP3393522B1 (en) * 2015-12-22 2021-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
AU2018350700B2 (en) 2017-10-16 2025-04-24 VeonGen Therapeutics GmbH AAV vectors
EP3898996A1 (en) * 2018-12-20 2021-10-27 Vigeneron GmbH An optimized acceptor splice site module for biological and biotechnological applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
WO2014170480A1 (en) * 2013-04-18 2014-10-23 Fondazione Telethon Effective delivery of large genes by dual aav vectors

Also Published As

Publication number Publication date
CN113474460A (zh) 2021-10-01
IL284021A (en) 2021-08-31
KR20210125472A (ko) 2021-10-18
US20220160898A1 (en) 2022-05-26
KR102938671B1 (ko) 2026-03-11
SG11202106356QA (en) 2021-07-29
IL284021B1 (en) 2026-08-01
AU2019406702A1 (en) 2021-06-10
JP2025060848A (ja) 2025-04-10
JP7668737B2 (ja) 2025-04-25
WO2020127831A1 (en) 2020-06-25
CA3122909A1 (en) 2020-06-25
EP3898996A1 (en) 2021-10-27
US12502438B2 (en) 2025-12-23
JP2022515606A (ja) 2022-02-21

Similar Documents

Publication Publication Date Title
US12502438B2 (en) Optimized acceptor splice site module for biological and biotechnological applications
KR102957630B1 (ko) 핵산 구조체 및 사용 방법
US20240318149A1 (en) AAV Vectors
JP7182873B2 (ja) 多重ベクターシステム及びその使用
US20210017509A1 (en) Gene Editing for Autosomal Dominant Diseases
AU2019226526B2 (en) Identifying and characterizing genomic safe harbors (GSH) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified GSH loci
JP2024096438A (ja) ゲノム編集の方法及び構築物
EP2982758A1 (en) Genome editing for the treatment of huntington's disease
JP2019533440A (ja) ジストロフィン遺伝子を改変しジストロフィン発現を回復させる方法およびその使用
US20250361525A1 (en) Aav vectors for gene editing
CA3097004A1 (en) Trans-splicing molecules
WO2021222654A1 (en) Compositions and methods for treatment of inherited macular degeneration
JP7739017B2 (ja) 筋強直性ジストロフィーの処置
WO2024069144A1 (en) Rna editing vector
US20220409744A1 (en) Method of transactivating a homologous gene of a gene of interest and an in vitro method of diagnosing a disease
WO2025231487A1 (en) Photoreceptor specific promotors for use in gene therapies for treatment of retinal degeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: VEONGEN THERAPEUTICS GMBH

Free format text: FORMER NAME(S): VIGENERON GMBH